A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9–Engineered T Cells (CTX110) in Subjects with Relapsed or Refractory B-Cell Malignancies

CRISPR Therapeutics AG0 个研究点目标入组 95 人开始时间: 2019年5月28日最近更新: 2020年2月1日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: CRISPR Therapeutics AG
入组人数: 95

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

入选标准

•1. Age =18 years.
•2. Able to understand and comply with protocol-required study procedures and voluntarily sign a written informed consent document.
•3. Diagnosed with 1 of the following histologically-confirmed (2016 World Health Organization
•classification) B-cell non-Hodgkin lymphomas: DLBCL NOS, high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, transformed FL, grade 3b FL, or Richter’s transformation of CLL.
•Confirmation of tumor histology from local pathology lab (archival tissue from last relapse [within 3 months of enrollment] or biopsy during screening).
•At least 1 lesion that is fluorodeoxyglucose positron emission tomography–positive, as defined by Lugano criteria (score of 4 or 5 on Lugano criteria 5-point scale). Note: Previously irradiated lesions will be considered measurable only if progression is documented following completion of radiation therapy.
•For NHL expansion cohort, subjects with Richter’s transformation of CLL will be excluded.
•4. Refractory or relapsed disease, as evidenced by 2 or more lines of prior therapy, including an anti-CD20 monoclonal antibody and an anthracycline-containing regimen, AND either have failed prior autologous hematopoietic stem cell transplantation (HSCT) OR ineligible for or refused prior autologous HSCT. Subjects who have received autologous HSCT must have recovered from HSCT-related toxicities.
•For refractory disease, subjects must have progressive disease on last therapy, or have stable disease following at least 2 cycles of therapy with duration of stable disease of up to 6 months.
•For subjects with transformed FL, subjects must have received at least 1 line of chemotherapy for disease after transformation to DLBCL.
•5. Eastern Cooperative Oncology Group performance status 0 or 1.
•6. Meets criteria to undergo LD chemotherapy and CAR T cell infusion.
•7. Adequate organ function:
•Renal: Estimated glomerular filtration rate >50 ml/min/1.73 m^2.
•Liver: Aspartate transaminase or alanine transaminase <3 x upper limit of normal (ULN); total bilirubin <1.5xULN (for subjects with Gilbert’s syndrome, total bilirubin <2 mg/dL).
•Cardiac: Hemodynamically stable and left ventricle ejection fraction =45% by echocardiogram.
•Pulmonary: Oxygen saturation level on room air >91% per pulse oximetry.
•8. Female subjects of childbearing potential (postmenarcheal with an intact uterus and at least 1 ovary, who are less than 1 year postmenopausal) must agree to use acceptable method(s) of contraception from enrollment through at least 12 months after CTX110 infusion.
•9. Male subjects must agree to use effective contraception from enrollment through at least 12 months after CTX110 infusion.
•10. Agree to participate in an additional long-term follow-up study after completion of this study. Participation in the long-term follow-up study requires separate consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 55
•F.1.3 Elderly (>=65 years) yes

排除标准

•1. Eligible for and agrees to autologous HSCT.
•2. Treatment with the following therapies as described below:
•a. Prior treatment with any gene therapy or genetically modified cell therapy, including CAR T cells.
•b. Prior treatment with a CD19-directed antibody, bispecific T cell engager, or antibody-drug conjugate, unless there is confirmed CD19 expression (by immunohistochemistry or flow cytometry) after progression or relapse following most recent CD19-directed treatment.
•3. Prior allogeneic HSCT.
•4. Prior anaphylactic reaction to cyclophosphamide, fludarabine, or any of the excipients of CTX110 product.
•5. Detectable malignant cells from cerebrospinal fluid (CSF) or magnetic resonance imaging indicating brain metastases during screening, or a history of central nervous system (CNS) involvement by malignancy (CSF or imaging).
•6. History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement.
•7. Unstable angina, clinically significant arrhythmia, or myocardial infarction within 6 months of enrollment.
•8. Presence of bacterial, viral, or fungal infection that is uncontrolled or requires IV anti-infectives.
•9. Positive for presence of human immunodeficiency virus type 1 or 2, or active hepatitis B virus or hepatitis C virus infection. Subjects with prior history of hepatitis B or C infection who have documented undetectable viral load (by quantitative polymerase chain reaction or nucleic acid testing) are permitted.
•10. Previous or concurrent malignancy, except basal cell or squamous cell skin carcinoma, adequately resected and in situ carcinoma of cervix, or a previous malignancy that was completely resected and has been in remission for =5 years.
•11. Radiation therapy within 14 days of enrollment.
•12. Use of systemic anti-tumor therapy or investigational agent within 14 days or 5 half-lives, whichever is longer, of enrollment. An exception is made for prior inhibitory/stimulatory immune checkpoint molecule therapy, which is prohibited within 3 half-lives of enrollment.
•13. Primary immunodeficiency disorder or active autoimmune disease requiring steroids and/or other immunosuppressive therapy.
•14. Diagnosis of significant psychiatric disorder or other medical condition that, in the opinion of the investigator, could impede the subject’s ability to participate in the study.
•15. Women who are pregnant or breastfeeding.

研究者

发起方

CRISPR Therapeutics AG

相似试验

进行中（未招募）

1 期

Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab Solid Tumors and B-cell Non-Hodgkins Lymphoma

EUCTR2014-002241-22-DEBristol-Myers Squibb International Corporation260

进行中（未招募）

1 期

Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab Solid Tumors and B-cell Non-Hodgkins Lymphoma

EUCTR2014-002241-22-ESBristol-Myers Squibb International Corporation260

进行中（未招募）

1 期

Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

EUCTR2014-002605-38-ATBristol-Myers Squibb International Corporation2,000

进行中（未招募）

1 期

EUCTR2014-002605-38-Outside-EU/EEABristol-Myers Squibb International Corporation

进行中（未招募）

1 期

Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumorseoplasms by siteMedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10067821Term: Head and neck cancer Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10067946Term: Renal cell carcinoma Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10017758Term: Gastric cancer Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10053571Term: Melanoma Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10065147Term: Malignant solid tumor Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10005003Term: Bladder cancer Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10073071Term: Hepatocellular carcinoma Class: 100000004864

CTIS2023-508067-70-00Bristol Myers Squibb International Corporation2,000